2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH DENA BATTLE
Patient Perspectives on Cytoreductive Nephrectomy after the CARMENA Trial

VIEW ALL ASCO GU 2019 VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH OLIVER SARTOR
Overall Survival Benefit and Racial Disparities in African American Men with Metastatic Prostate Cancer

VIEW ALL PCF VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH KARIM FIZAZI
ARAMIS - Efficacy and Safety of Darolutamide in nmCRPC

VIEW ALL ASCO GU 2019 VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH JAMES GULLEY
Immunotherapy Across Genitourinary Malignancies

VIEW ALL ASCO GU 2019 VIDEOS

Featured Videos

EAU 2014 - Prevention of symptomatic skeletal events in patients with genitourinary (GU) tumours and bone metastases treated with denosumab or zoledronic acid - Session Highlights

STOCKHOLM, SWEDEN (UroToday.com) - Patients who develop bone metastases from prostate cancer are at risk for skeletal complications that may seriously impact function and quality of life. Denosumab and zoledronic acid (ZA) are approved for the prevention of skeletal complications from bone metastases in solid tumors. Denosumab has demonstrated superiority over ZA for the prevention of skeletal-related events (SREs). An alternative study endpoint of symptomatic skeletal events (SSE), defined as symptomatic fracture, surgery or radiation to bone, or spinal cord compression) was introduced to describe these bone complications. Dr. K. Fizazi and colleagues compared the benefit of denosumab versus ZA in preventing SSEs in patients with advanced GU tumors and bone metastases.

eauPatients with advanced GU tumors, at least one bone metastasis, and no prior IV bisphosphonate use were randomized to receive either denosumab or ZA every 4 weeks in a double-blind fashion. The risk of first SSE was reduced by 22% in patients treated with denosumab versus ZA. There were also fewer overall SSEs and a longer time to first-and-subsequent on-study SSEs in patients treated with denosumab versus ZA. Fewer SSEs of all types were observed in the denosumab treatment group. Denosumab reduced the risk of skeletal complications in patients with GU cancers and bone metastases regardless of whether the endpoint was defined as SRE or SSE. Because all skeletal complications from bone metastases have the potential to negatively affect patients’ function and quality of life, preventive treatment should be considered even when symptoms are not present.

Presented by K. Fizazi at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

Institut Gustave Roussy, University of Paris-Sud, Paris, France

Written by Jeffrey J. Tomaszewski, MD, medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 3 Issue 4

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe